ClinicalTrials.gg
CompletedNCT01317641Updated Mar 29, 2017Results posted

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

A Phase 1/2 interventional study of ODM-201 in Prostate Cancer, sponsored by Orion Corporation, Orion Pharma. Completed at 23 sites in 6 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-29.

Sponsored by Orion Corporation, Orion Pharma · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.

Enrollment
23rd of 59
136 · median 80
Started
2011
with 1 other
Phase 1/2
3 of 59
1 open now
Registered
1st of 59
by date
Lead sponsor
3 of 59
Orion Corporation, Orion Pharma

Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 23rd largest by enrollment, is one of 2 that started in 2011, is one of 3 in phase 1/2, and was the 1st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About darolutamide

darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing darolutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • confirmed adenocarcinoma of prostate
  • Ongoing androgen deprivation therapy with a LHRH analogue or antagonist or bilateral orchiectomy
  • Progressive disease
  • Adequate bone marrow, hepatic, and renal function

Exclusion criteria

Exclusion Criteria:

  • Known in the brain
  • History of other within the previous 5 years
  • Known gastrointestinal disease or procedure that affects the absorption
  • Not able to swallow the study drug
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    ODM-201 Phase I

    Drug: ODM-201

  • Experimental
    ODM-201 Phase II Dose 1

    Drug: ODM-201

  • Experimental
    ODM-201 Phase II Dose 2

    Drug: ODM-201

  • Experimental
    ODM-201 Phase II Dose 3

    Drug: ODM-201

Interventions

  • ODM-201 administered orally daily

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants Who Experienced Dose Limiting Toxicity (DLT)

    A DLT was any Grade 3 or more toxicity (by National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE version 4.03\]) excluding less than Grade 4 neutropenia or thrombocytopenia, hematological toxicity lasting less than 7 days, and nausea, vomiting, diarrhea controlled with antiemetic and/or anti-diarrheal treatment.

    Time frame: Up to 28 days for each cohort

  2. Phase 1: Number of Dose Limiting Toxicities Used to Determine the Maximum Tolerated Dose

    The MTD is defined as dose level at which 2 or more out of 6 participants experience a dose limiting toxicity (DLT)

    Time frame: Up to 28 days for each cohort

Secondary outcomes

  1. Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Chemotherapy-naïve and CYP17i-naïve Group

    Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants who were naïve to both chemotherapy and CYP17 inhibitor

    Time frame: 3 months

  2. Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-chemotherapy and CYP17i-naïve Group

    Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants previously treated with chemotherapy but not CYP17 inhibitor

    Time frame: 3 months

  3. Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-CYP17i Group

    Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants previously treated with CYP17 inhibitor

    Time frame: 3 months

  4. Phase 1 and 2: Participants With RECIST Response in Soft Tissue in Chemotherapy-naïve and CYP17i-naïve Group

    Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.

    Time frame: 3 months

  5. Phase 1 and 2: Participants With RECIST Response in Soft Tissue in Post-chemotherapy and CYP17i-naive Group

    Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.

    Time frame: 3 months

  6. Phase 1 and 2: Participants With RECIST Responses in Soft Tissue in Post-CYP17i Group

    Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.

    Time frame: 3 months

  7. Phase 1 and 2: Participants With Stable Bone Disease in Chemotherapy-naïve and CYP17i-naïve Group

    Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan

    Time frame: 3 months

  8. Phase 1 and 2: Participants With Stable Bone Disease in Post-chemotherapy and CYP17i-naïve Group

    Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan

    Time frame: 3 months

  9. Phase 1 and 2: Participants With Stable Bone Disease in Post-CYP17i Group

    Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan

    Time frame: 3 months

  10. Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of ODM-201 at Steady-state

    AUC(0-8h)

    Time frame: Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose

  11. Phase 1: Maximum Plasma Concentration (Cmax) of ODM-201 at Steady-state

    Time frame: Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose

  12. Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of ODM-201 at Day 1

    Time frame: 1 day

  13. Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of Major Metabolite ORM-15341 at Steady-state

    AUC(0-8h)

    Time frame: Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose

  14. Phase 1: Maximum Plasma Concentration (Cmax) of Major Metabolite ORM-15341 at Steady-state

    Time frame: Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose

  15. Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of Major Metabolite ORM-15341 at Day 1

    Time frame: 1 day

07

Results

Posted Mar 29, 2017

Participant flow

Participants were enrolled at 23 hospitals in Europe and in the USA from Apr 5, 2011 to Mar 12, 2013

Participant flow — Overall Study
MilestonePhase 1: ODM-201 200 mg/DayPhase 1: ODM-201 400 mg/DayPhase 1: ODM-201 600 mg/DayPhase 1: ODM-201 1000 mg/DayPhase 1: ODM-201 1400 mg/DayPhase 1: ODM-201 1800 mg/DayPhase 2: ODM-201 200mg/DayPhase 2: ODM-201 400mg/DayPhase 2: ODM-201 1400mg/Day
Started473433383836
Completed363333353331
Not completed110100355
Withdrew: Not treated000000011
Withdrew: Adverse event010100210
Withdrew: Protocol violation100000000
Withdrew: Disease progression000000034
Withdrew: Withdrawal by subject000000100

Outcome measures

PrimaryPhase 1: Number of Participants Who Experienced Dose Limiting Toxicity (DLT)

A DLT was any Grade 3 or more toxicity (by National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE version 4.03\]) excluding less than Grade 4 neutropenia or thrombocytopenia, hematological toxicity lasting less than 7 days, and nausea, vomiting, diarrhea controlled with antiemetic and/or anti-diarrheal treatment.

Time frame:
Up to 28 days for each cohort
Reported as:
Number · events
Phase 1: Number of Participants Who Experienced Dose Limiting Toxicity (DLT)
eventsPhase 1: ODM-201 200 mg/DayPhase 1: ODM-201 400 mg/DayPhase 1: ODM-201 600 mg/DayPhase 1: ODM-201 1000 mg/DayPhase 1: ODM-201 1400 mg/DayPhase 1: ODM-201 1800 mg/Day
Phase 1: Number of Participants Who Experienced Dose Limiting Toxicity (DLT)000000
PrimaryPhase 1: Number of Dose Limiting Toxicities Used to Determine the Maximum Tolerated Dose

The MTD is defined as dose level at which 2 or more out of 6 participants experience a dose limiting toxicity (DLT)

Time frame:
Up to 28 days for each cohort
Reported as:
Number · DLTs
Phase 1: Number of Dose Limiting Toxicities Used to Determine the Maximum Tolerated Dose
DLTsPhase 1: ODM-201 200 mg/DayPhase 1: ODM-201 400 mg/DayPhase 1: ODM-201 600 mg/DayPhase 1: ODM-201 1000 mg/DayPhase 1: ODM-201 1400 mg/DayPhase 1: ODM-201 1800 mg/Day
Phase 1: Number of Dose Limiting Toxicities Used to Determine the Maximum Tolerated Dose000000
SecondaryPhase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Chemotherapy-naïve and CYP17i-naïve Group

Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants who were naïve to both chemotherapy and CYP17 inhibitor

Time frame:
3 months
Reported as:
Number · participants
Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Chemotherapy-naïve and CYP17i-naïve Group
participants200mg/Day ODM-201400mg/Day ODM-201600mg/Day ODM-2011000mg/Day ODM-2011400mg/Day ODM-2011800mg/Day ODM-201
Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Chemotherapy-naïve and CYP17i-naïve Group691162
SecondaryPhase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-chemotherapy and CYP17i-naïve Group

Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants previously treated with chemotherapy but not CYP17 inhibitor

Time frame:
3 months
Reported as:
Number · participants
Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-chemotherapy and CYP17i-naïve Group
participants200mg/Day ODM-201400mg/Day ODM-201600mg/Day ODM-2011000mg/Day ODM-2011400mg/Day ODM-2011800mg/Day ODM-201
Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-chemotherapy and CYP17i-naïve Group511140
SecondaryPhase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-CYP17i Group

Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants previously treated with CYP17 inhibitor

Time frame:
3 months
Reported as:
Number · participants
Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-CYP17i Group
participants200mg/Day ODM-201400mg/Day ODM-2011000mg/Day ODM-2011400mg/Day ODM-201
Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-CYP17i Group0301
SecondaryPhase 1 and 2: Participants With RECIST Response in Soft Tissue in Chemotherapy-naïve and CYP17i-naïve Group

Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.

Time frame:
3 months
Reported as:
Number · participants
Phase 1 and 2: Participants With RECIST Response in Soft Tissue in Chemotherapy-naïve and CYP17i-naïve Group
participants200mg/Day ODM-201400mg/Day ODM-201600mg/Day ODM-2011400mg/Day ODM-2011800mg/Day ODM-201
RECIST response CR+PR14010
RECIST response CR+PR+SD96222
SecondaryPhase 1 and 2: Participants With RECIST Response in Soft Tissue in Post-chemotherapy and CYP17i-naive Group

Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.

Time frame:
3 months
Reported as:
Number · participants
Phase 1 and 2: Participants With RECIST Response in Soft Tissue in Post-chemotherapy and CYP17i-naive Group
participants200mg/Day ODM-201400mg/Day ODM-2011000mg/Day ODM-2011400mg/Day ODM-2011800mg/Day ODM-201
RECIST response CR+PR10010
RECIST response CR+PR+SD53041
SecondaryPhase 1 and 2: Participants With RECIST Responses in Soft Tissue in Post-CYP17i Group

Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.

Time frame:
3 months
Reported as:
Number · participants
Phase 1 and 2: Participants With RECIST Responses in Soft Tissue in Post-CYP17i Group
participants200mg/Day ODM-201400mg/Day ODM-2011400mg/Day ODM-201
RECIST response CR+PR020
RECIST response CR+PR+SD596
SecondaryPhase 1 and 2: Participants With Stable Bone Disease in Chemotherapy-naïve and CYP17i-naïve Group

Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan

Time frame:
3 months
Reported as:
Number · participants
Phase 1 and 2: Participants With Stable Bone Disease in Chemotherapy-naïve and CYP17i-naïve Group
participants200mg/Day ODM-201400mg/Day ODM-2011000mg/Day ODM-2011400mg/Day ODM-2011800mg/Day ODM-201
Phase 1 and 2: Participants With Stable Bone Disease in Chemotherapy-naïve and CYP17i-naïve Group107161
SecondaryPhase 1 and 2: Participants With Stable Bone Disease in Post-chemotherapy and CYP17i-naïve Group

Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan

Time frame:
3 months
Reported as:
Number · participants
Phase 1 and 2: Participants With Stable Bone Disease in Post-chemotherapy and CYP17i-naïve Group
participants200mg/Day ODM-201400mg/Day ODM-201600mg/Day ODM-2011000mg/Day ODM-2011400mg/Day ODM-201
Phase 1 and 2: Participants With Stable Bone Disease in Post-chemotherapy and CYP17i-naïve Group54107
SecondaryPhase 1 and 2: Participants With Stable Bone Disease in Post-CYP17i Group

Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan

Time frame:
3 months
Reported as:
Number · participants
Phase 1 and 2: Participants With Stable Bone Disease in Post-CYP17i Group
participants200mg/Day ODM-201400mg/Day ODM-2011000mg/Day ODM-2011400mg/Day ODM-201
Phase 1 and 2: Participants With Stable Bone Disease in Post-CYP17i Group5916
SecondaryPhase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of ODM-201 at Steady-state

AUC(0-8h)

Time frame:
Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose
Reported as:
Mean · h*ng/mL
Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of ODM-201 at Steady-state
h*ng/mL200 mg/Day ODM-201400 mg/Day ODM-201600 mg/Day ODM-2011000 mg/Day ODM-2011400 mg/Day ODM-2011800 mg/Day ODM-201
Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of ODM-201 at Steady-state6387.27 ± 742.0110973.66 ± 5939.7814205.99 ± 2127.2614817.39 ± 4190.4831764.82 ± 8714.0628884.44 ± 4900.60
SecondaryPhase 1: Maximum Plasma Concentration (Cmax) of ODM-201 at Steady-state
Time frame:
Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose
Reported as:
Mean · ng/mL
Phase 1: Maximum Plasma Concentration (Cmax) of ODM-201 at Steady-state
ng/mL200 mg/Day ODM-201400 mg/Day ODM-201600 mg/Day ODM-2011000 mg/Day ODM-2011400 mg/Day ODM-2011800 mg/Day ODM-201
Phase 1: Maximum Plasma Concentration (Cmax) of ODM-201 at Steady-state1011.67 ± 168.841757.57 ± 858.722033.00 ± 277.592392.33 ± 406.634459.00 ± 1163.104235.00 ± 617.80
SecondaryPhase 1: Time to Reach the Maximum Observed Concentration (Tmax) of ODM-201 at Day 1
Time frame:
1 day
Reported as:
Median · h
Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of ODM-201 at Day 1
h200 mg/Day ODM-201400 mg/Day ODM-201600 mg/Day ODM-2011000 mg/Day ODM-2011400 mg/Day ODM-2011800 mg/Day ODM-201
Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of ODM-201 at Day 13.00 ± 1.633.00 ± 0.733.00 ± 0.925.08 ± 1.473.00 ± 1.155.00 ± 1.51
SecondaryPhase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of Major Metabolite ORM-15341 at Steady-state

AUC(0-8h)

Time frame:
Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose
Reported as:
Mean · h*ng/mL
Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of Major Metabolite ORM-15341 at Steady-state
h*ng/mL200 mg/Day ODM-201400 mg/Day ODM-201600 mg/Day ODM-2011000 mg/Day ODM-2011400 mg/Day ODM-2011800 mg/Day ODM-201
Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of Major Metabolite ORM-15341 at Steady-state11754.23 ± 5161.8015501.56 ± 2755.8524902.56 ± 12129.7929980.83 ± 11658.7563531.81 ± 15798.3064435.97 ± 22930.30
SecondaryPhase 1: Maximum Plasma Concentration (Cmax) of Major Metabolite ORM-15341 at Steady-state
Time frame:
Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose
Reported as:
Mean · ng/mL
Phase 1: Maximum Plasma Concentration (Cmax) of Major Metabolite ORM-15341 at Steady-state
ng/mL200 mg/Day ODM-201400 mg/Day ODM-201600 mg/Day ODM-2011000 mg/Day ODM-2011400 mg/Day ODM-2011800 mg/Day ODM-201
Phase 1: Maximum Plasma Concentration (Cmax) of Major Metabolite ORM-15341 at Steady-state1850.00 ± 654.832491.43 ± 328.863963.33 ± 1935.214643.33 ± 1340.019336.67 ± 2054.279406.67 ± 3165.38
SecondaryPhase 1: Time to Reach the Maximum Observed Concentration (Tmax) of Major Metabolite ORM-15341 at Day 1
Time frame:
1 day
Reported as:
Median · h
Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of Major Metabolite ORM-15341 at Day 1
h200 mg/Day ODM-201400 mg/Day ODM-201600 mg/Day ODM-2011000 mg/Day ODM-2011400 mg/Day ODM-2011800 mg/Day ODM-201
Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of Major Metabolite ORM-15341 at Day 13.00 ± 1.631.52 ± 1.333.00 ± 0.925.04 ± 2.053.00 ± 1.155.00 ± 0.55

Adverse events

Collected over 3 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1, 200mg/Day ODM-201—0/4 (0%)4/4 (100%)
Phase 1, 400mg/Day ODM-201—2/7 (28.6%)5/7 (71.4%)
Phase 1, 600mg/Day ODM-201—0/3 (0%)2/3 (66.7%)
Phase 1, 1000mg/Day ODM-201—1/4 (25%)4/4 (100%)
Phase 1, 1400mg/Day ODM-201—1/3 (33.3%)3/3 (100%)
Phase 1, 1800mg/Day ODM-201—0/3 (0%)2/3 (66.7%)
Phase 2, 200mg/Day ODM-201—2/38 (5.3%)33/38 (86.8%)
Phase 2, 400mg/Day ODM-201—3/37 (8.1%)35/37 (94.6%)
Phase 2, 1400mg/Day ODM-201—4/35 (11.4%)27/35 (77.1%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPhase 1, 200mg/Day ODM-201Phase 1, 400mg/Day ODM-201Phase 1, 600mg/Day ODM-201Phase 1, 1000mg/Day ODM-201Phase 1, 1400mg/Day ODM-201Phase 1, 1800mg/Day ODM-201Phase 2, 200mg/Day ODM-201Phase 2, 400mg/Day ODM-201Phase 2, 1400mg/Day ODM-201
Urinary retentionRenal and urinary disorders0/40/70/30/41/30/30/380/370/35
Hand fractureInjury, poisoning and procedural complications0/40/70/31/40/30/30/380/370/35
LacerationInjury, poisoning and procedural complications0/40/70/31/40/30/30/380/370/35
Muscle injuryInjury, poisoning and procedural complications0/40/70/31/40/30/30/380/370/35
General physical health deteriorationGeneral disorders0/41/70/30/40/30/30/380/370/35
Staphylococcal infectionInfections and infestations0/41/70/30/40/30/30/380/370/35
Cerebral ischaemiaNervous system disorders0/41/70/30/40/30/30/380/370/35
PneumoniaInfections and infestations0/40/70/30/40/30/30/380/371/35
Back painMusculoskeletal and connective tissue disorders0/40/70/30/40/30/30/381/371/35
Bone painMusculoskeletal and connective tissue disorders0/40/70/30/40/30/30/380/371/35
Most frequent other events
Showing 10 of 66
Most frequent other events
EventPhase 1, 200mg/Day ODM-201Phase 1, 400mg/Day ODM-201Phase 1, 600mg/Day ODM-201Phase 1, 1000mg/Day ODM-201Phase 1, 1400mg/Day ODM-201Phase 1, 1800mg/Day ODM-201Phase 2, 200mg/Day ODM-201Phase 2, 400mg/Day ODM-201Phase 2, 1400mg/Day ODM-201
DiarrhoeaGastrointestinal disorders3/41/71/30/40/32/30/384/371/35
GynaecomastiaReproductive system and breast disorders0/40/70/30/42/30/31/381/370/35
Oedema peripheralGeneral disorders2/40/70/30/41/30/32/380/374/35
StomatitisGastrointestinal disorders2/40/70/30/40/30/30/380/370/35
AstheniaGeneral disorders2/42/70/30/40/30/30/381/370/35
MyalgiaMusculoskeletal and connective tissue disorders2/40/70/30/40/30/31/380/370/35
ConstipationGastrointestinal disorders1/41/70/30/40/31/35/386/372/35
NauseaGastrointestinal disorders1/40/70/31/40/31/34/384/373/35
FatigueGeneral disorders0/40/70/31/41/31/37/388/375/35
Hot flushVascular disorders0/40/70/30/40/31/32/384/372/35

Baseline characteristics

Safety

Age, Continuous
Age, Continuous(years)Phase 1, 200mg/Day ODM-201Phase 1, 400mg/Day ODM-201Phase 1, 600mg/Day ODM-201Phase 1, 1000mg/Day ODM-201Phase 1, 1400mg/Day ODM-201Phase 1, 1800mg/Day ODM-201Phase 2 (200mg/Day ODM-201)Phase 2 (400mg/Day ODM-201)Phase 2 (1400mg/Day ODM-201)Total
Mean73 ± 1.471.9 ± 8.565.3 ± 3.565.8 ± 11.267.7 ± 5.567.7 ± 3.268.3 ± 7.069.1 ± 7.471.3 ± 8.069.4 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1, 200mg/Day ODM-201Phase 1, 400mg/Day ODM-201Phase 1, 600mg/Day ODM-201Phase 1, 1000mg/Day ODM-201Phase 1, 1400mg/Day ODM-201Phase 1, 1800mg/Day ODM-201Phase 2 (200mg/Day ODM-201)Phase 2 (400mg/Day ODM-201)Phase 2 (1400mg/Day ODM-201)Total
Female0000000000
Male473433383735134
08

Study locations

23 sites
  • The Urology Center of Colorado
    Wheat Ridge, Colorado 80211, United States
  • Eastern CT Hematology and Oncology Associates
    Norwich, Connecticut 06360, United States
  • Urology Health Team PLLC
    Ocala, Florida 34474, United States
  • Chesapeake Urology Research Associates
    Baltimore, Maryland 21327, United States
  • Delaware Valley urology, LLC
    Voorhees, New Jersey 08043, United States
  • Brooklyn Urology Research Group
    Brooklyn, New York 11215, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Klinika onkologie a radioterapie LFUK a FN
    Hradec Králové, Czech Republic
  • Fakultni Nemonicnice Olomouc
    Olomouc, Czech Republic
  • Oddeleni Radiacni a Klinicke Onkologie Nemocnice Znojmo
    Znojmo, Czech Republic
  • East-Tallinn Central Hospital
    Talinn, Estonia
  • Helsinki University Central Hospital
    Helsinki, Finland
  • Kuopio University Hospital
    Kuopio, Finland
  • Oulu University Hospital
    Oulu, Finland
  • Tampere University Hospital
    Tampere, Finland
  • Turku University Hospital
    Turku, Finland
  • Saint Louis Hospital
    Paris, France
  • Institut Gustave Roussy
    Villejuif, France
  • Queen Elizabeth Hospital
    Birmingham, United Kingdom
  • Velindre Cancer Centre
    Cardiff, United Kingdom
  • Christie Hospital
    Manchester, United Kingdom
  • Churchill Hospital
    Oxford, United Kingdom
09

References and documents

Publications

  • Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, Vuorela A, Langmuir P, Mustonen M; ARADES study group. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014 Aug;15(9):975-85. doi: 10.1016/S1470-2045(14)70240-2. Epub 2014 Jun 25. PubMed 24974051 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2011
First posted
Mar 17, 2011
Start
Mar 2011
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Results first posted
Mar 29, 2017
Last update
Mar 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01317641
Responsible party
Sponsor
First posted
Mar 17, 2011
Start date
Mar 2011
Primary completion
Jul 2013
Completion
Jul 2013
Results posted
Mar 29, 2017
Last update
Mar 29, 2017

Study contacts

Karim Fizazi
principal investigator · Gustave Roussy, Cancer Campus, Grand Paris

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darolutamide

Start the discussion